Monique Martin
SVP, Value & Evidence, Europe
Expertise:
Monique Martin is a seasoned professional with extensive experience spanning over two decades in the pharmaceutical and healthcare industries. Before joining EVERSANA, Monique served as the Global Head of Evidence Synthesis, Modeling and Market Access Communications at a major global consultancy, where she was instrumental in driving strategic initiatives, uniting three business units, and driving financial success. She also held leadership positions at various major international consultancies, honing her expertise in market access, pricing and reimbursement.
With a background in health economics and business development, she has consistently contributed to the advancement of healthcare solutions throughout her career. Monique is based out of London in the United Kingdom and holds multiple postgraduate degrees from various UK and European universities.
Articles by Monique Martin
The Integral Role of Global Indirect Treatment Comparison in Europe’s JCA
Discover the integral role of Global Indirect Treatment Comparison (ITC) Programs in Europe’s Joint Clinical Assessment (JCA) in this insightful piece by EVERSANA. Learn why a global ITC program is not just beneficial but essential for market access and health technology assessment (HTA) submissions. The article delves into the mission of the JCA and the imperative of a global ITC program, especially in areas where direct comparisons are not feasible. It also provides a blueprint for achieving excellence in a global ITC program, emphasizing early engagement, strategic partnerships and analytical depth. EVERSANA’s HEOR team, with its experience in conducting 400+ ITC analyses and launching 20+ global ITC programs, emerges as […]
European Parliament’s Revision of the General Pharmaceutical Legislation
The European Parliament has adopted a revision of the general pharmaceutical legislation, repealing and amending previous legislation with a set of compromise amendments. According to the European Commission, it has been called “the largest reform in over 20 years.” In this POV, EVERSANA’s experts, Mike Ryan, GM, Europe and Monique Martin, SVP, Value and Evidence, share information about the revision, its meaning, implications and importance, and what the amendments could mean if they ultimately become law. While this is not yet final legislation, the article offers best courses of action for Marketing Authorization Holders with the aim to improve equitable access to medicines, make the region more innovation-friendly and streamline […]